PedAM
Pediatric Disease Annotations & Medicines
| Disease | uveitis |
| Phenotype | C0004943|behcet\'s disease |
| Sentences | 19 |
| PubMedID- 22220161 | Oct-based retinal thickness analysis in the eyes of behcet's disease patients with uveitis revealed a correlation between retinal thickness decrease and an increase in the duration of uveitis [7]. |
| PubMedID- 24939422 | Changes in subfoveal choroidal thickness associated with uveitis activity in patients with behcet's disease. |
| PubMedID- 23630362 | Role of il-22- and tnf-alpha-producing th22 cells in uveitis patients with behcet's disease. |
| PubMedID- 24424168 | Posterior uveitis is associated with behcet's disease and hla-b51. |
| PubMedID- 20029140 | [6] its efficacy has been proven beyond doubt in the treatment of systemic diseases such as rheumatoid arthritis (ra), juvenile idiopathic arthritis (jia), as well as endogenous, non-infectious refractory uveitis associated with behcet's disease and sarcoidosis. |
| PubMedID- 22750994 | Mean platelet volume does not seem to relate to thrombosis or posterior uveitis in behcet's disease. |
| PubMedID- 21958178 | The earliest was interferon-alpha, and a multitude of reports have described its benefits for the uveitis associated with behcet's disease. |
| PubMedID- 23090423 | Purpose: to report a case of psoriasis triggered by anti-tumor necrosis factor-alpha (tnf-alpha) therapy in a uveitis patient with behcet's disease. |
| PubMedID- 19816689 | Infliximab has demonstrated remarkable effects on controlling uveitis in patients with behcet's disease (bd). |
| PubMedID- 23316652 | In behcet's disease patients with active uveitis, among the various costimulatory molecules, the inducible costimulator (icos), an active form of stimulatory molecule, is most strongly expressed, and is associated with cytokine production by th1 and th17 cells. |
| PubMedID- 20542984 | Timing of recurrent uveitis in patients with behcet's disease receiving infliximab treatment. |
| PubMedID- 24683491 | Specifically, ivta has been effectively used to treat uveitis associated with behcet's disease [83–85], vkh syndrome [86], serpinginous choroiditis [87], and sympathetic ophthalmia [88–91]. |
| PubMedID- 24994946 | The aim of the present study was to determine the serum cytokine profile and levels of high sensitivity c-reactive protein (hscrp) in patients with uveitis associated with behcet's disease (bd) and to compare them with those obtained from healthy control subjects. |
| PubMedID- 24492505 | Most of the biologics mainly infliximab have been proven to be very effective in the treatment of severe refractory uveitis especially in patients with behcet's disease. |
| PubMedID- 24199188 | Table 8 shows treatment of uveitis in behcet's disease. |
| PubMedID- 24835134 | behcet's disease was a representative of vision loss uveitis because behcet's patient usually had treatment resistance of conventional treatment, such as colchicine and cyclosporine. |
| PubMedID- 22546542 | Inhibition of th17 differentiation by anti-tnf-alpha therapy in uveitis patients with behcet's disease. |
| PubMedID- 23470459 | Several open prospective studies have shown the effectiveness of ifn-alpha (78 to 98% complete remission) for the treatment of severe uveitis in behcet's disease. |
| PubMedID- 20135752 | The evaluated parameters were similar in behcet's disease patients with and without uveitis, and pathergy-positive and pathergy-negative groups. |
Page: 1